
p1 "Optimizing intravesical therapy in Octogenarians with non-muscle invasive bladder cancer"



Chatterton K, Amery S, Zisengwe G, Kinsella J, Dickinson F, O'Brien TS

The Urology Centre, Guy's and St Thomas' NHS Foundation Trust, London, UK

Guy's and St Thomas' MHS Foundation Trust

Introduction

Understanding bladder cancer in the elderly should be an important goal of every bladder cancer service. At our institution a third of patients with bladder cancer are aged over eighty. As nurses we have addressed the specific issue of the tolerability of intravesical therapy within this cohort of patients, due to the frequency of coexistent lower urinary tract symptoms (LUTS).

Between 2008 and 2011, we carried out a retrospective analysis of all octogenarian patients treated with intravesical therapy within our nurse-led clinic, assessing tolerability of treatment.

Results

30 patients were identified with non muscle invasive bladder cancer (NMIBC) who underwent intravesical therapy , including: BCG + maintenance, Mitomycin (MMC) or sequential BCG / EMDA MMC.

A median age of 81. Tolerance to treatment was monitored and documented.

- 23% of patients had LUTS which limited treatment
- 13% of which did not complete the prescribed course
- 10% had an interrupted course of treatment, potentially compromising successful treatment outcome
- Only one patient was assessed for LUTS prior to treatment, subsequently underwent bladder outflow

7/30 (23%) recurred after

intravesical treatment

(2 progressed)

obstruction surgery, treatment commenced post surgery

Final TNM classification at initial diagnosis:

G2 (low) pTa	1
G3 pTa	11
G3 pT1	15
No Histology	1
Primary CIS	2
Secondary CIS	11

Guy's and St Thomas' NHS Foundation Trust	
BCG Check List	
Patient Label Here	
Proposed course of Treatment:	
Di Stasi 🗆 6 x BCG 🗆 Maintenance BCG 🗆	
Contra-indications:	-
Impaired immune responseYesImpairedNoHIVYesNoImpairedActive TBYesNoImpairedUnexplained feverYesNoImpairedPregnancy/Breast FeedingYesNoImpaired	
Is patient on warfarin? Yes No If yes, arrange alternative anti-coagulation as required	-
LUTS assessment:	
Flowrate Yes No Residual volume:	
Require treatment for LUTS? Yes No Safe to proceed with treatment? Yes No	
Date of operation: Histology: Intended treatment start date:	
Verbal consent from patient for treatment:	
Drug prescribed:	
Doctors signature: Date:	

2 patients have undergone cystectomy; 6 died (3 related to bladder cancer); 22 currently on flexible cystoscopy f/up +/- maintenance therapy.

Despite the fact that the potential for LUTS in this group is much higher, we found that LUTS assessments were not routinely done prior to commencement of intravesical treatment.



All patients should have a LUTS assessment prior to commencement of nurse-led intravesical therapy.

Nurses administering treatment have an ethical and professional responsibility to ensure this is carried out to improve treatment tolerance and outcome.